ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 950,17
0,11%
Dow Jones
44 544,66
-0,75%
DAX
21 732,05
0,01%
Brent Oil
76,385
0,00%
Bitcoin
102 423,31
0,01%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Sangamo Therapeutics Inc (SGMO) Cours

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

NASDAQ
1,22
-0,01
(-0,81%)
Fermé 01 Février 10:00PM
Retardé de 15 minutes
1,211
-0,009
(-0,74%)
Après les heures de négociation: 1:50AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
1,211
Prix Achat
1,22
Prix Vente
1,25
Volume échangé
4 015 396
1,18 Fourchette du Jour 1,2852
0,304 Plage de 52 semaines 3,179
Cap du marché
252,671M
Clôture Veille
1,23
Ouverture
1,2385
Dernière Transaction
150
@
1.211
(formt)
Dernière heure de transaction
Volume financier
US$ 4 909 069
VWAP
1,2226
Volume moyen (3 m)
7 639 953
Actions en circulation
208 646 870
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,99
Bénéfice par action (BPA)
-1,24
Chiffre d'affairess
176,23M
Bénéfice net
-257,83M

À propos de Sangamo Therapeutics Inc

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.sangamo.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Sangamo Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker SGMO. Le dernier cours de clôture d'Sangamo Therapeutics était de US$1,23. Au cours de la dernière année, les actions de Sangamo Therapeutics ont été négociées dans une fourchette de prix de US$ 0,304 à US$ 3,179.

Sangamo Therapeutics compte actuellement 208 646 870 actions en circulation. La capitalisation boursière d'Sangamo Therapeutics est de US$256,64 million. Sangamo Therapeutics a un ratio cours/bénéfice (ratio PE) de -0.99.

SGMO Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

24 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

30 Décembre 2024
Edgar (US Regulatory)

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential...

30 Décembre 2024
Business Wire

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire TOKYO and RICHMOND, Calif., Dec. 19, 2024  - Agreement...

19 Décembre 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

26 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.0110.9166666666671.21.291.0840063981.16484339CS
40.0514.396551724141.161.51156475651.19612506CS
12-1.679-58.09688581312.893.1790.9176399531.88425842CS
260.51674.24460431650.6953.1790.640184822751.47096111CS
520.7325153.0825496340.47853.1790.30473168651.14006963CS
156-4.499-78.79159369535.716.420.291135804481.62012866CS
260-5.949-83.08659217887.1619.430.291128004843.70903519CS

SGMO - Frequently Asked Questions (FAQ)

What is the current Sangamo Therapeutics share price?
The current share price of Sangamo Therapeutics is US$ 1,211
How many Sangamo Therapeutics shares are in issue?
Sangamo Therapeutics has 208 646 870 shares in issue
What is the market cap of Sangamo Therapeutics?
The market capitalisation of Sangamo Therapeutics is USD 256,64M
What is the 1 year trading range for Sangamo Therapeutics share price?
Sangamo Therapeutics has traded in the range of US$ 0,304 to US$ 3,179 during the past year
What is the PE ratio of Sangamo Therapeutics?
The price to earnings ratio of Sangamo Therapeutics is -0,99
What is the cash to sales ratio of Sangamo Therapeutics?
The cash to sales ratio of Sangamo Therapeutics is 1,44
What is the reporting currency for Sangamo Therapeutics?
Sangamo Therapeutics reports financial results in USD
What is the latest annual turnover for Sangamo Therapeutics?
The latest annual turnover of Sangamo Therapeutics is USD 176,23M
What is the latest annual profit for Sangamo Therapeutics?
The latest annual profit of Sangamo Therapeutics is USD -257,83M
What is the registered address of Sangamo Therapeutics?
The registered address for Sangamo Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Sangamo Therapeutics website address?
The website address for Sangamo Therapeutics is www.sangamo.com
Which industry sector does Sangamo Therapeutics operate in?
Sangamo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,87M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,57M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,58M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,91M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,93k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
900,48k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,42M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,54M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
338,75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,29M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
234,8M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
SGMO
Sangamo Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces